Skip to main content

Investor Relations

Induced pluripotent stem cells (iPSCs) are at the core of our business.

Heavily commercialized since their discovery in 2006, iPSCs  can be used to generate any tissue type including cardiac muscle, nerves, liver, and blood.

iPSCs have a variety of applications including disease modeling, drug screening, and regenerative medicine.

 

Key Advantages of iPSCs

iPSCs have several advantages over medical technologies using other cell types.

  • iPSCs can differentiate (transform) into any other type of cell in the human body
  • iPSCs can multiply indefinitely, making them ideally suited for research and medicine
  • iPSCs are produced from the cells of the patient, so carry a reduced risk of transplant rejection
  • iPSCs avoid the ethical concerns of embryonic stem cells
ir-ips-cells-1

Applications of iPSCs

iPSCs can transform into any other cell and multiply easily granting them a wide range of applications.

Beyond their research capabilities, iPSCs have the potential for use in personalized medicine and donor-free regenerative treatments. Already, huge advances have been made in innovation in medical biotechnology as a result of the commercialization of iPSC technologies. Below, we have summarized the key products and services currently offered by REPROCELL and which customers they target.

ir-ips-cells-2

Research Reagents

At REPROCELL, we produce and sell reagents for iPSC research. These highly specialized reagents vary based on the type of iPSC, plus the methods used for multiplication and measurement. Products we offer researchers include culture fluids, dissociation solutions, preservation solutions, coatings, and antibodies.

Target customers:

  • Public research organizations e.g. universities
  • Private research organizations e.g. drug manufacturers
ir-ips-cells-3

Drug Discovery

We also produce iPSC-derived cells for use in drug discovery screening including patient-derived Alzheimer’s disease cells. These can be used by pharmaceutical companies to effectively evaluate the safety and efficacy of drug candidates. It is hoped that sophisticated in vitro models like these will largely replace animal testing in the future. 

Target customers:

  • Public research organizations e.g. universities
  • Private research organizations e.g. drug manufacturers
ir-ips-cells-4

Precision Medicine

In the future, iPSCs derived from a patient’s tissues could be used to assess treatment compatibility and identify the ideal dosing schedule for an individual patient.

Target customers: 

  • Individual patients
  • Public and private hospitals
ir-ips-cells-5

Regenerative Medicine

Until now, regenerative medicine has relied on a limited supply of tissues from human donors. As iPSCs can multiply indefinitely, they could be used to create an unlimited supply of somatic cells for transplantation, eliminating the need for tissue donors. At REPROCELL, we offer a GMP-grade iPSC master cell bank service that can be used to produce iPSCs for use in the clinical setting.

Target customers:

  • Patients
  • Hospitals

REPROCELL’s Growth Strategy

Across the globe, iPSC research is advancing. New technologies are broadening their applications in medical biotechnology. By responding to the market’s increasing demands with high-quality human iPSC-based products, we can expand and grow our business.

Our venture fund, Cell Innovation Partners, L.P., was established in partnership with the Shinsei Bank Group. It aims to acquire promising novel technologies, targeting ventures related to iPSCs or regenerative medicine and proactively investing globally.

ir-growth-strategy-1-1

Public Assistance and Development of Laws

As a growing industry, we are supported by the government in Japan.

As part of its growth plan, the Japanese administration has pledged 110 billion yen over 10 years to support medical research using iPSCs. It has also established a “Japanese National Institutes of Health”, based on the USA’s  NIH, and has revised the Pharmaceutical Affairs Law to approve medical technologies quicker.

REPROCELL’s headquarters is based in a special zone for iPSC Research 

We are based in Yokohama City, Kanagawa Prefecture, which is part of the Life Innovation in Keihin Coastal Areas “Comprehensive Special Zones for International Competitiveness Development”". This zone aims to increase international competitiveness by allowing global businesses to lead medicine and medical equipment production, helping related industries and SMEs prosper.

The legislation in Japan supports regenerative medicine

Two laws came into effect on November 25, 2014. These not only clarified the standards and processes for regenerative medicine products but also accelerated the approval process:

  1. The “Law on Guaranteeing Safety in Regenerative Medicine” or “Regenerative Medicine Law”
  2. The “Law on Guaranteeing Safety, Efficacy, and Quality in Medical Supplies and Equipment”, also called the “Medical Supplies and Equipment Law”
ir-competitive-edge-1

REPROCELL’s Competitive Edge

As a growing industry, we are supported by the government in Japan.

As part of its growth plan, the Japanese administration has pledged 110 billion yen over 10 years to support medical research using iPSCs. It has also established a “Japanese National Institutes of Health”, based on the USA’s  NIH, and has revised the Pharmaceutical Affairs Law to approve medical technologies quicker.

REPROCELL’s headquarters is based in a special zone for iPSC Research

We are based in Yokohama City, Kanagawa Prefecture, which is part of the Life Innovation in Keihin Coastal Areas “Comprehensive Special Zones for International Competitiveness Development”". This zone aims to increase international competitiveness by allowing global businesses to lead medicine and medical equipment production, helping related industries and SMEs prosper.

The legislation in Japan supports regenerative medicine

Two laws came into effect on November 25, 2014. These not only clarified the standards and processes for regenerative medicine products but also accelerated the approval process:

  1. The “Law on Guaranteeing Safety in Regenerative Medicine” or “Regenerative Medicine Law”
  2. The “Law on Guaranteeing Safety, Efficacy, and Quality in Medical Supplies and Equipment”, also called the “Medical Supplies and Equipment Law”
ir-competitive-edge-1

Safe Harbor Statement

Statements made on our website with respect to current plans, estimates, strategies, and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of REPROCELL Incorporated and REPROCELL Incorporated Group.

From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments, and beliefs in light of the information currently available to it. REPROCELL Incorporated cautions you that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, and therefore you should not place undue reliance on them. You also should not rely on any obligation of REPROCELL Incorporated to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. REPROCELL Incorporated disclaims any such obligation. Risks and uncertainties that might affect REPROCELL Incorporated include, but are not limited to:

  1. The global economic environment which REPROCELL Incorporated or customer of REPROCELL Incorporated operates
  2. Fluctuation in foreign exchange rates
  3. Changes in the laws, regulations, and government policies in the jurisdictions where REPROCELL Incorporated operates
  4. Political and economic instability in the jurisdictions where REPROCELL Incorporated operates
  5. REPROCELL Incorporated’s ability to:
    1. Develop and introduce new products in a timely manner
    2. Recoup large-scale investments required for technology development and production capacity
    3. Devote sufficient resources to research and development
    4. Maintain product quality
    5. Forecast demands, manage timely procurement, and control inventories Risks related to catastrophic disasters or similar events

The REPROCELL group and its global partners are developing several more preclinical and clinical therapeutic services around the world. Following are a few examples.

personal-ips-banner-2

Personal iPS Service

REPROCELL’s Personal iPS service allows clients to generate and store iPSCs for use in future regenerative medicine treatments. Currently, iPSCs are being investigated for the treatment of several diseases, including age-related macular degeneration (AMD), Parkinson’s Disease (PD), and ischemic heart disease (CHD).

Our Personal iPS service is aimed at parents who want to make potential iPSC-based therapeutics available to their children later in life. These iPSCs are reprogrammed from cells contained in the child's urine or baby teeth to avoid invasive skin biopsy or blood draw procedures. Personal iPS use non-integrating RNA technology to reprogram these cells into iPSCs which are stored in the US and Japan. 

A key benefit of generating these iPSCs at a young age is that the cells are less likely to contain harmful genetic mutations. Storing them in advance of illness/injury also reduces potential treatment delays.

en.personalips.com

well-mill-banner-3

Well-Mill Testing Kits

Our Well-Mill testing kits allow customers to obtain blood readings for specific health concerns. Derived from the Japanese word "mill" which means "seeing", this service checks the levels of circulating hormones and other proteins.

Well-Mill testing kits can be purchased from our B2C website. Blood samples are collected by the customer using a finger prick draw and are returned to our laboratories via post. Well-Mill provides blood readings for specific health concerns, including stress (cortisol), menopause (estradiol, testosterone), allergy (total IgE), and many more.

This service is currently available to customers in Japan.

well-mill.com
(Japanese language website)

COVID PCR Testing

In 2021 we launched a high throughput Covid-19 identification service to contribute to the end of the pandemic. This PCR-based method uses SmartAmp and Allplex screening to identify coronavirus variants. The Allplex system can simultaneously detect:

  • HV69/70 del mutation found in the UK variant
  • E484K found in the South African and Brazilian variants
  • N501Y found in all three novel variants

Read our official press release

PreciONC Oncology

Bioserve India

Our pharmacogenomics assays can help clinicians to make better decisions about treatment choices and prescribing. These integrated molecular diagnostic solutions can assist at every stage of the cancer journey:

  • Hereditary risk assessment
  • Diagnosis and Prognosis
  • Treatment selection and monitoring
  • Disease surveillance

PreciONC Oncology diagnostics
(Bioserve India)

New Therapeutic Strategies

At REPROCELL, we are developing new strategies for treating rare central nervous system diseases.

We currently have two therapeutic products in our clinical pipeline, one made from Glial-restricted Progenitor Cells (GRPs) and another from Mesenchymal Stem Cells (MSCs).

Our GRP therapeutic is being developed in the United States, while the MSC being trailed in Taiwan, Japan, Korea, and the USA.

Products currently available in our therapeutic pipeline:

21JAN20 Glial Restricted Progenitor Cells GRPjpg

Q-cell GRP Cell Therapy

Our iPSC-GRPs are being developed in collaboration with Q Therapeutics Inc. in the United States. Preclinical iPSC-GRP research is currently taking place in our cGMP cell processing suite, located at the Life Innovation Center in Japan. So far, these therapeutics have demonstrated efficacy in the treatment of Amyotrophic Lateral Sclerosis and Transverse myelitis.

21JAN20 Mesnchymal Stem Cells MSC-3

Stemchymal MSC therapy

Stemchymal® is an allogenic cellular therapy derived from Mesenchymal stem cells. The therapeutic is being developed by Steminent Biotherapeutics, whom REPROCELL have an exclusive co-development and sale agreement with in Japan. Results from early stage clinical trials suggest that Stemchymal is safe for intravenous administration in humans. Phase II clinical trials are now underway to estimate efficacy of the treatment in patients with Spinocerebellar Ataxia.

Download our Corporate Capabilities Brochure (PDF)

Find out more about the services and products we offer to better translate your discoveries into therapies.

Upcoming Events

Conferences and meetings we will be attending, and webinars hosted by us.

International Conference on Cancer & Oncology Research

15-16 April / London, UK
REPROCELL/Bioserve booth

Swiss Biotech Day 2024

22-23 April / Congress Center Basel, Switzerland

ISCT 2024 Annual Meeting

29-31 May / Vancouver,Canada
Booth #322